

Fourth meeting: Unmet challenges in high-risk haematological malignancies: from benchside to clinical practice

**Turin, STARHOTELS MAJESTIC
March 26-27, 2026**

Scientific Board:
Marco Ladetto
Umberto Vitolo

Scientific Committee
Benedetto Bruno
Gianluca Gaidano
Massimo Massaia
Adriano Venditti
Valeria Santini

PROGRAMMA

Thursday March 26, 2026

09.15 Welcome and introduction

Marco Ladetto (Alessandria, Italy), Umberto Vitolo (Candiolo-TO, Italy) and scientific authorities

09.45 - 11.15 SESSION 1: LARGE B-CELL LYMPHOMA

Chairmen: Alice Di Rocco (Roma, Italy), Francesco Zaja (Trieste, Italy)

09.45 DEBATE

Molecularly driven vs agnostic treatment strategies in first line DLBCL.

Georg Lenz (Munster, Germany) vs Catherine Thieblemont (Paris, France)

10.25 The evolving landscape in R/R DLBCL: bispecifics, ADC and novel engineered antibodies

Marek Trneny (Praha, Czech Republic)

10.45 CNS prophylaxis: an old chap or a still valid option?

Andres J.M. Ferreri (Milano, Italy)

11.05 Panel Discussion

10.00 – 11.00 OPEN COFFEE

11.15 - 12.55 SESSION 2: HODGKIN LYMPHOMA AND T-CELL LYMPHOMA

Chairmen: Andrea R. Filippi (Milano, Italy), Luigi Rigacci (Roma, Italy)

11.15 DEBATE

Minimizing Toxicity and preserving efficacy in early-stage Hodgkin lymphoma:

the radiation oncology perspective

Umberto Ricardi (Torino, Italy)

the chemoimmunotherapy perspective

Igor Aurer (Zagreb, Croatia)

11.55 DEBATE

Immunochemotherapy-Based Strategies for Sparing Toxicity and Improving Efficacy in Advanced-Stage Hodgkin Lymphoma:

Beacopp-based (Peter Borchmann, Cologne Germany) vs AVD-based Pier Luigi Zinzani (Bologna, Italy)

12.35 How I treat high risk T-cell Lymphomas

Annalisa Chiappella (Milano, Italy)

12.55 – 13.45 Lunch

13.45-14.15 LECTURE 1

Chairman: Umberto Vitolo (Candiolo-TO, Italy)

The paradigm shift in the treatment of follicular lymphoma: from chemoimmunotherapy to bispecific antibodies and small molecules combination

Gilles Salles (New York, USA)

14.15 - 15.35 SESSION 3: INDOLENT LYMPHOMA

Chairmen: Annarita Conconi (Biella, Italy), Guido Gini (Ancona, Italy)

14.15 Biology of high-risk indolent lymphoma

Jessica Okosun (London, UK)

14.35 First line treatment in high-risk follicular lymphoma

Stefano Luminari (Modena, Italy)

14.55 Waldenström Macroglobulinemia: from chemoimmunotherapy to chemo-free approaches

Christian Buske (Ulm, Germany)

15.15 Panel Discussion

15.25 – 16.35 SESSION 4: MANTLE CELL LYMPHOMA

Chairmen: Monica Balzarotti (Rozzano-MI, Italy), Maurizio Martelli (Roma, Italy)

15.25 How MRD detection is changing in the era of BTKi in MCL

Christiane Pott (Kiel, Germany)

15.45 The role of BTK inhibitors in first line MCL therapy

Mats Jerkeman (Lund, Sweden)

16.05 Chemo-free approaches in relapsed/refractory Mantle Cell Lymphoma

Carlo Visco (Verona, Italy)

16.25 Panel Discussion

16.30 – 17.30 OPEN COFFEE

16.45 - 17.15 LECTURE 2

Chairman: Marco Ladetto (Alessandria, Italy)

Novel Frontiers with CART treatment in B-cell Malignancies

Marie Josè Kersten (Amsterdam-The Netherlands)

17.15 - 18.25 SESSION 5: CHRONIC LYMPHOCYTIC LEUKEMIA

Chairmen: Antonio Cuneo (Ferrara, Italy), Massimo Massaia (Torino, Italy)

- | | | |
|-------------|--|--|
| 17.15 | Biology of high risk CLL and acquired resistance | Davide Rossi (Bellinzona, Switzerland) |
| 17.35 | Role of combination treatment in first line | O. Al-Sawaf (Cologne, Germany) |
| 17.55 | How I treat BTKi failures | Wojciech Jurczak (Krakow, Poland) |
| 18.15-18.25 | Panel Discussion | |

Friday, March 27, 2024

08.30 - 10.00 SESSION 6: MULTIPLE MYELOMA

Chairmen: Benedetto Bruno (Torino, Italy), Sara Bringhen (Cuneo, Italy)

08.30 Static and dynamic prognostic factors in Multiple Myeloma: roles of disease biology and MRD
Mattia D'Agostino (Torino, Italy)

09.30 – 10.30 OPEN COFFEE

08.50 DEBATE

CAR-T vs. Bispecific Antibodies: Real Roles in Real life.

CAR-T Francesca Gay (Torino, Italy) vs Bispecifics K. Ramasamy (Oxford, UK)

09.30 New Clinical Trails: integration of new therapies and MRD
Cyrille Touzeau (Nantes, France)

09.50 Panel Discussion

10.00-11.10 SESSION 7: Myelodysplastic Syndrome

Chairmen: Daniela Cilloni (Torino, Italy), Valeria Santini (Firenze, Italy)

10.00 DEBATE

TP53-Mutated MDS: Is Transplant the Only Way?

Yes - David Varcacel (Barcelona, Spain)

No - Katharina Goetze (Munich, Germany)

10.40 Symptomatic anemia in MDS: when and how to treat
Elena Crisà (Candiolo-TO, Italy)

11.00 Panel discussion

11.10 - 11.50 SESSION 8: Access disparity to novel treatments as a novel “High Risk”

Chairman: Robin Foà (Roma, Italy), Gianluca Gaidano (Novara, Italy)

11.10 Current situation and how to foster access in medium income countries Adela Perolla (Tirana, Albania)

11.30 The role of international societies in promoting worldwide access to modern diagnosis and treatment

Gianluca Gaidano (Novara, Italy)

11.50 Panel discussion

12.00-13.00 Lunch

13.00 - 14.10 SESSION 9: ACUTE LYMPHOBLASTIC LEUKEMIA

Chairmen: Alessandro Busca (Torino, Italy), Daniela Pietrasanta (Alessandria, Italy)

- 13.00 Biology of High Risk ALL Monika Brueggemann (Kiel, Germany)
- 13.20 The evolving strategies in the treatment of young adults and elderly patients with Acute Lymphoblastic Leukemia Alessandro Rambaldi (Bergamo, Italy)
- 13.40 Allogeneic transplant and CART in adult ALL: which comes first? Nicola Goekbuget (Frankfurt, Germany)
- 14.00 Panel Discussion

14.10-15.20 SESSION 10: ACUTE MYELOBLASTIC LEUKEMIA

Chairmen: Giuseppe Saglio (Torino, Italy), Adriano Venditti (Roma, Italy)

- 14.10 Biologic features of HR-AML Raffaele Palmieri (Roma, Italy)
- 14.30 High risk AML: how to incorporate new drugs into the treatment of AML Priyanka Metha (Bristol, UK)
- 14.50 Allogenic stem cell transplant in HR-AML Charlie Craddock (Birmingham, UK)
- 15.10 Panel Discussion

15.20 – 15.30 CLOSING REMARKS

Marco Ladetto (Alessandria, Italy), Umberto Vitolo (Candiolo-TO, Italy)